# Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas

> **NCT02271945** · PHASE1,PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 10 (actual)

## Conditions studied

- Relapsed/Refractory Aggressive B-cell Lymphomas

## Interventions

- **DRUG:** MEDI-551 12 mg/kg
- **DRUG:** MEDI0680 2.5 mg/kg
- **DRUG:** MEDI0680 10 mg/kg

## Key facts

- **NCT ID:** NCT02271945
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-01
- **Primary completion:** 2016-05-24
- **Final completion:** 2016-05-24
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2018-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02271945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02271945, "Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02271945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*